bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on BLUE. Baird R W lowered bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Barclays lowered their target price on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. Finally, Wells Fargo & Company dropped their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, February 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $44.60.

bluebird bio Price Performance

Shares of NASDAQ:BLUE opened at $4.09 on Monday. bluebird bio has a one year low of $3.56 and a one year high of $28.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The company has a market cap of $40.04 million, a price-to-earnings ratio of -0.11 and a beta of 0.41. The firm has a 50 day simple moving average of $4.47 and a 200 day simple moving average of $7.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in shares of bluebird bio by 3.7% during the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after acquiring an additional 166,771 shares in the last quarter. State Street Corp raised its stake in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after purchasing an additional 43,382 shares during the last quarter. Barclays PLC lifted its holdings in shares of bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares in the last quarter. Finally, Regeneron Pharmaceuticals Inc. purchased a new position in shares of bluebird bio during the fourth quarter valued at approximately $175,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.